Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: apreliminary study [Expression of concern

Abstract

Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study [Expression of concern] Huang L, Li G, Zhu J, Li Z, Li T, Leng X. Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study. Onco Targets Ther. 2012;5:457–462. The Editor-in-Chief and Publisher of OncoTargets and Therapy wish to issue an Expression of Concern for the published article. Concerns have been raised that the study described in the article did not adhere to ethical guidelines as outlined in the Declaration of Helsinki and the Declaration of Istanbul and guidance from the World Health Organization and the World Medical Association regarding the source of transplanted human organs. Specifically, the British Medical Journal Open (BMJ Open) published an article highlighting many papers in which there is concern that transplanted organs were harvested from executed prisoners in China. In response to these concerns we contacted the authors to clarify the source of the transplanted organs received by the patients described in their study. However, despite multiple attempts to contact the authors and their institutions, no response was received. The Editors of OncoTargets and Therapy would like to alert readers of this. We will provide an update if we receive any further information. OncoTargets and Therapy publishes research adhering to internationally accepted ethical standards and is committed to upholding the Declaration of Helsinki and Declaration of Istanbul. Dove Medical Press endorses the ethics guidelines described by the World Health Organization (WHO) and the World Medical Association (WMA). Read the original article